Table 1.
Top 10 cited articles in immunotherapy on breast cancer from 2010 to 2019.
| Author | Country | Title | Total citations |
|---|---|---|---|
| Nanda, R. | USA | [8] in patients with advanced triple-negative breast cancer: Phase IB KEYNOTE-012 Study | 715 |
| Gianni, L. | Italy | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease | 452 |
| Muenst, S. | Switzerland | Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer | 263 |
| Ren, X. B. | China | Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer | 238 |
| Miller, J. S. | USA | A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer | 219 |
| Stagg, J. | Canada | CD73 promotes anthracycline resistance and poor prognosis in triple-negative breast cancer | 191 |
| Maher, J. | England | Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling | 190 |
| Zardavas, D. | Belgium | Clinical management of breast cancer heterogeneity | 160 |
| Dieli, F. | Italy | In vivo manipulation of V gamma 9 V delta 2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients | 159 |
| Rimm, D. L. | USA | PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer | 157 |